• en
    Early-stage funding for European life sciences companies We are a venture capital firm specialised in seed investment for innovative early stage companies. BGV generally acts as lead investor. Our current portfolio comprises of biotech developing truly disruptive solutions for high unmet medical needs.
  • en
    Acerta, a multi-billion Euro success story BioGeneration was co-founder and investor in the most successful biotech startup in Europe: Acerta Pharma. Acerta Pharma has developed Calquence® (acalabrutinib), a drug now approved by the FDA for the treatment of hematologic malignancies (leukemia). Acerta was sold to AstraZeneca for up to US$ 7 billion in 2016.
  • en
    Shaping new life-science ventures We gained our experience from working within small and large pharma and biotech companies. Based on this experience and through our extensive industry network, we are able to bring a range of sector-relevant expertise to help accelerate product development and shape the companies to become attractive investment opportunities for the industry.

Latest News

Get to Know Us

BioGeneration Ventures leverages its knowledge gained from working with a diverse network.

This includes universities, early stage biotech companies and large pharma. We enable a range of sector-relevant expertise to build and accelerate product development and transform entrepreneurs and their companies to become attractive investment opportunities within the life sciences industry.

Read more

en

News

Learn about the latest developments at BioGeneration Ventures and what’s happening at our portfolio companies.

Show all

Portfolio

Our team adopts a hands-on approach. We work closely with our portfolio companies to review transactions that leverage operational and management expertise.

Show all
en
Meet the Team Where to find us Show events

The BGV team

We are a venture capital firm specialised in seed investment for innovative early stage companies. BGV generally acts as lead investor. Our team is made up of life science experts and business analysts that can guide life science companies’ development throughout the entire research and development process.

  • Arnoud Dijkstra

    Arnoud Dijkstra, PhD

    Venture Partner

    Arnoud is a venture partner with BGV and joined in 2018. He currently holds various positions in the management of BGV portfolio companies including VarmX and Staten Biotechnology.

    Read more
  • Robbert van de Griendt

    Robbert van de Griendt

    Head of Investment Relations

    At BGV, Robbert is responsible for Fundraising and Investor Relations. He also leads Forbion’s ESG and impact investing efforts.

    Read more
  • Machteld Groeneveld, LLM, EMBA

    Machteld Groeneveld, LLM, EMBA

    Legal Counsel & Compliance Officer

    Read more
  • Oskar Slotboom

    Oskar Slotboom

    General Partner

    Oskar joined BioGeneration as a partner in 2016 strengthening the team with his commercial, business development and consulting experience.

    Read more
  • Elena Ritsou

    Elena Ritsou , PhD

    Venture Partner

    Dr. Ritsou brings 20 years of experience in Corporate and Business Development in pharmaceutical and biotech companies.

    Read more
  • Daniela Couto

    Daniela Couto, PhD

    Partner

    Daniela previously was CEO at Cell2B, a life sciences company that she co-founded dedicated to treat immune and inflammatory diseases.

    Read more
  • John J.P. Kastelein

    John J.P. Kastelein, MD PhD FESC

    Senior Advisor

    Prof. Dr. John Kastelein is Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam.

    Read more
  • Wouter Verhoeven

    Wouter Verhoeven

    Venture Partner

    Wouter is a venture partner at BGV since 2021. He is currently CEO at Dualyx and will serve in interim management positions in portfolio companies of BGV.

    Read more
  • Edward van Wezel

    Edward van Wezel

    Managing Partner

    Edward currently serves on the supervisory boards of Azafaros, Escalier BioSciences, Genase Therapeutics, Scenic Biotech, Staten Biotechnology, Synaffix and TigaTx.

    Read more
  • Rob de Ree

    Rob de Ree

    Venture Partner

    Rob is venture partner at BGV since 2016, serving on the board and in interim management positions in the fund’s portfolio companies.

    Read more
  • Rianne Ellenbroek

    Rianne Ellenbroek, PhD

    Principal

    Rianne Ellenbroek is Principal and works across all BGV funds.

    Read more
  • Cyril Lesser

    Cyril Lesser

    Senior Controller

    Cyrill is Senior Controller and his main focus lies in the financial and treasury operations as well as the accounting and tax reporting.

    Read more

Subscribe